Reclast (Zoledronic Acid) Label Updates 2020 to 2026: FDA Safety Changes Explained

Reclast is the brand name for zoledronic acid 5 mg/100 mL solution for intravenous infusion, approved by the FDA for osteoporosis and Paget's disease of bone. It is a different product, dose, and indication set from Zometa, which is zoledronic acid 4 mg/5 mL concentrate approved for hypercalcemia of malignancy and bone metastases in cancer. The two are sometimes confused in hospital pharmacies because they share the same active ingredient, and that confusion has been a documented source of dosing errors.

The direct answer

Reclast carries no boxed warning as a class matter for the osteoporosis indication, but its Warnings and Precautions section addresses renal impairment, hypocalcemia, osteonecrosis of the jaw, and atypical femoral fracture, and FDA-approved generic zoledronic acid 5 mg/100 mL products must carry equivalent safety language because of Reference Listed Drug labeling requirements. The specific wording, thresholds, and dates of individual label supplements change over time and are not reliably reproduced here; readers who need the current label text for prescribing or dispensing decisions should retrieve it directly from the FDA's Drugs@FDA database for NDA 021817, dated to the day they check it.

What this article can and cannot verify

Established, and unlikely to be controversial: Reclast's FDA approval for osteoporosis, its once-yearly 5 mg IV dosing format, its distinction from the Zometa formulation, and the general presence of renal, hypocalcemia, ONJ, and atypical fracture warnings in bisphosphonate labeling.

Plausible but not confirmed in this draft: the exact year-by-year sequence of Reclast label supplements between 2020 and 2024, specific numeric thresholds (such as an exact eGFR cutoff), specific adverse event counts from FAERS, and specific relative-risk or hazard-ratio figures attributed to named studies. The source material reviewed for this article did not include a verifiable copy of the current Reclast label or a confirmed primary study matching each numeric claim, so those figures have been removed rather than repeated with a false sense of precision.

Not established from any source used here: any claim that a specific 2020, 2021, 2022, 2023, or 2024 labeling supplement added a specific sentence of text. That level of detail would need to come from a verified copy of the historical label revisions, which was not available for this draft.

Why the renal, ONJ, and fracture themes matter regardless of exact dates

Three safety themes recur across bisphosphonate labeling generally and are worth understanding even without a confirmed supplement timeline for Reclast specifically.

Kidney function. Zoledronic acid is renally cleared, and bisphosphonate labels as a class restrict use below a certain kidney function threshold and call for a current creatinine or eGFR check before dosing. The exact numeric cutoff and testing window in the current Reclast label should be confirmed directly from the Prescribing Information rather than assumed, since these values are the kind of detail that can be revised in a supplement.

Atypical femoral fracture (AFF). All bisphosphonates, including zoledronic acid, carry warning language about atypical subtrochanteric or femoral shaft fractures that can occur with minimal trauma, typically after several years of continuous therapy. The FDA-convened American Society for Bone and Mineral Research task force has published guidance on recognizing and managing AFF, and that guidance is a reasonable reference point for clinicians, but the exact incidence figures cited in any secondary source should be checked against the current task force report rather than taken on faith.

Osteonecrosis of the jaw (ONJ). ONJ is a recognized, uncommon complication of bisphosphonate therapy, more strongly associated with high-dose oncology regimens than with once-yearly osteoporosis dosing. Dental evaluation before starting therapy, particularly in patients with active dental disease, poor oral hygiene, or a history of head-and-neck radiation, is a widely recommended precaution, though the precise incidence range for the osteoporosis dose should be verified against current labeling rather than an inherited number.

Hypocalcemia and vitamin D status. Pre-existing hypocalcemia is a contraindication to bisphosphonate infusion, and low vitamin D status is a recognized risk factor for symptomatic hypocalcemia after dosing. Correcting vitamin D deficiency before infusion is standard practice in bone specialty care, independent of the exact numeric threshold used in any particular label version.

Dosing framework as generally described in osteoporosis and Paget's labeling

Reclast for osteoporosis is dosed as a single 5 mg intravenous infusion given over at least 15 minutes, once yearly. For Paget's disease, a single 5 mg infusion is used, with re-treatment considered only if disease activity markers or symptoms indicate relapse rather than on a fixed schedule. These are long-standing, well-known features of the drug's dosing format rather than a recent label change, and they should still be confirmed against the current Prescribing Information before any clinical use, since this article does not substitute for that document and does not provide individualized dosing advice.

Drug holidays: a guideline concept, not a label mandate

Professional guidance on bisphosphonate treatment duration, including work from the American Society for Bone and Mineral Research, has discussed the concept of a "drug holiday" after a period of years of continuous therapy in lower-risk patients, with reassessment of ongoing fracture risk. This is guideline-level reasoning about long-term treatment strategy, not a dosing instruction from the FDA label itself, and the right duration for any individual patient depends on fracture history, bone density trend, and other risk factors that a treating clinician needs to weigh directly. This article does not recommend a specific holiday length for any individual reader.

Special populations

Bisphosphonates including zoledronic acid are not approved for use in children, largely because of concern about effects on an immature growth plate and limited pediatric trial data. In pregnancy, bisphosphonates accumulate in bone and can theoretically be released over a long period after the drug is stopped, which is why prescribing information for this drug class generally advises avoiding use in patients who are pregnant or trying to conceive, and effective contraception during treatment. Data on use during breastfeeding are limited. None of this is a substitute for an individualized discussion between a patient and their treating clinician, particularly for anyone of reproductive age being considered for this therapy.

Generic substitution

Zoledronic acid 5 mg/100 mL has multiple FDA-approved generic manufacturers. Under standard FDA generic drug rules, an approved generic's labeling must track the Reference Listed Drug's safety language, so a safety update to the Reclast label is expected to propagate to generic labeling as well. A separate, off-label practice exists in some hospital settings of reconstituting the oncology formulation (Zometa, 4 mg/5 mL) for osteoporosis dosing; this is not the FDA-approved product or concentration for that indication and carries a recognized risk of dosing confusion between the two strengths.

Before-infusion decision framework

This is a general screening framework for organizing the recognized safety questions around an annual zoledronic acid infusion. It is not a substitute for the current Prescribing Information, and it does not set a numeric threshold that this article cannot verify. Use it as a conversation structure with the prescribing clinician, not as a standalone clinical protocol.

If any answer suggests an unresolved medical concern, urgent new symptoms (such as sudden vision loss, severe unexplained leg pain, or signs of an allergic reaction) warrant contacting a clinician or seeking urgent care rather than waiting for the next scheduled infusion.

When to seek urgent care rather than waiting for a routine visit

Sudden, severe thigh or groin pain, signs of a jaw infection or exposed bone, sudden vision changes, or symptoms of severe hypocalcemia such as muscle cramping, tingling around the mouth, or an irregular heartbeat are reasons to contact a clinician promptly rather than waiting for the next scheduled infusion or annual visit. This article cannot tell an individual reader whether a given symptom is an emergency; that determination requires a clinician's direct assessment.

What we could not verify for this draft

This article intentionally omits a supplement-by-supplement chronology of Reclast label changes from 2020 through 2026, specific adverse event counts, and specific statistical estimates (relative risks, hazard ratios, odds ratios) that appeared in an earlier draft, because those figures could not be traced to a verifiable primary source during this review. A clinician or medical reviewer with direct access to the historical Reclast labeling archive on Drugs@FDA and the underlying published studies would be needed to responsibly restore that level of detail.